New azetidine derivatives, pharmaceutical compositions and uses thereof

A compound of the formula I

• wherein
• Ar1 is selected from a group consisting of:
• 6- to 10-membered aryl and 5- to 10-membered heteroaryl, which are each substituted with one or more substituents R1,
• wherein two substituents R1 linked to adjacent C-atoms of Ar1 together may form a C3-5-alkylene bridge, in which 1, 2 or 3 CH2-groups may be replaced by O, C(═O), S, S(═O), S(═O)2, NH or N(C1-4-alkyl),
• and wherein the alkylene bridge may optionally be substituted by one or two C1-3-alkyl groups;
• while
• R1 is selected from a group consisting of:
• H, F, Cl, Br, I, CN, OH, —NO2, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-10-carbocyclyl, C3-10-carbocyclyl-C1-3-alkyl, C1-6-alkyl-O—, C3-6-alkenyl-O—, C3-6-alkynyl-O—, C3-10-carbocyclyl-O—, C3-10-carbocyclyl-C1-3-alkyl-O—, C1-6-alkyl-S—, C1-6-alkyl-S(═O)—, C1-6-alkyl-S(═O)2—, C3-10-carbocyclyl-S—, C3-10-carbocyclyl-C1-3-alkyl-S—, C1-4-alkyl-C(═O)—, C3-10-carbocyclyl-C(═O)—, R3R4N—, R3R4N—C2-3-alkyl-O—, R3R4N—C(═O)—, R3R4N—S(═O)2—, C1-6-alkyl-C(═O)—NR3—, C1-6-alkyl-S(═O)2—NR3—, C1-6-alkyl-C(═O)—NR3—C1-3-alkyl-, HO—C(═O)—, C1-6-alkyl-O—C(═O)—, heterocyclyl, heterocyclyl-O—, heterocyclyl-C1-3-alkyl, heterocyclyl-C1-3-alkyl-O—, heterocyclyl-C(═O)—, heterocyclyl-NR4—, aryl, aryl-C1-3-alkyl, aryl-O—, aryl-C1-3-alkyl-O—, heteroaryl, heteroaryl-C1-3-alkyl, heteroaryl-O— and heteroaryl-C1-3-alkyl-O—,
• wherein in each carbocyclyl and heterocyclyl a CH2-group may be replaced by —C(═O)—, —C═CH2—, —C═CH(C1-6-alkyl)- or —C═C(C1-6-alkyl)2-,
• wherein each carbocyclyl and heterocyclyl may be substituted with one or more C1-4-alkyl, which may be substituted with one or more substituents R2,
• wherein each alkyl, carbocyclyl and heterocyclyl may be substituted with one or more substituents R2,
• wherein each heterocyclyl may be substituted with aryl or heteroaryl, and
• wherein each aryl and heteroaryl group may be substituted with one or more substituents R5;
• R2 is selected from a group consisting of:
• F, Cl, Br, CN, OH, C1-4-alkyl-O—, C3-7-cycloalkyl-O, C3-7-cycloalkyl-C1-3-alkyl-O—, H2N—, (C1-4-alkyl)NH—, (C1-4-alkyl)2N—, C1-4-alkyl-C(═O)—, C1-4-alkyl-S(═O)2—, HO—C(═O)— and C1-4-alkyl-O—C(═O)—,
• wherein each alkyl or cycloalkyl may be substituted with one or more substituents independently selected from F and OH;
• and
• R3 is selected from a group consisting of:
• H, C1-6-alkyl, C3-10-carbocyclyl, C3-10-carbocyclyl-C1-3-alkyl, C3-6-alkenyl, C3-6-alkynyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl and heteroaryl-C1-3-alkyl,
• wherein each carbocyclyl and heterocyclyl may be substituted with one or more C1-4-alkyl,
• wherein in each carbocyclyl and heterocyclyl one CH2-group may be replaced by —C(═O)—,
• wherein each alkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group may be substituted with one or more substituents R5,
• R4 is H or C1-6-alkyl;
• and
• Ar2 is selected from a group consisting of:
• phenylene and a 5- or 6-membered monocyclic heteroarylene group containing 1, 2 or 3 heteroatoms independently selected from N, O, or S,
• wherein each of the groups mentioned above for Ar2 may be substituted with one or more substituents R6;
• and
• R5 is selected from a group consisting of:
• F, Cl, Br, CN, OH, C1-4-alkyl-, C1-4-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(═O)2—, C1-3-alkyl-O—(C═O)—, H2N—, (C1-4-alkyl)NH—, (C1-4-alkyl)2N—, C1-4-alkyl-C(═O)—NH—, C1-4-alkyl-C(═O)—N(C1-4 alkyl)- and heterocyclyl,
• wherein each alkyl may be optionally substituted with one or more F-atoms and/or with a substituent selected from OH, C1-3-alkyl-O— and CN;
• and wherein two substituents R6 attached to an aryl or heteroaryl group together may form a C2-5-alkylene bridge, in which 1 or 2-CH2-groups may be replaced by a group independently selected from O, S, NH and N(C1-4-alkyl)-, and wherein the C2-5-alkylene bridge is optionally be substituted by 1 or 2 C1-3-alkyl groups;
• L is
• a straight chain C1-4-alkylene group which is optionally substituted with one or more C1-3-alkyl or C1-3-alkyl-O—C1-3-alkyl groups,
• wherein two alkyl substituents together may form a C1-5-alkylene bridge in which 1 or 2-CH2-groups may be replaced by a group independently selected from O, S, NH or N(C1-4-alkyl)-, and wherein the C1-5-alkylene bridge is optionally substituted by 1 or 2 C1-3-alkyl groups;
• and
• R is H or C1-3-alkyl;
• and
• T is selected from a group consisting of:
• C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-10-carbocyclyl, C3-10-carbocyclyl-C1-3-alkyl, C1-6-alkyl-O—, C3-10-carbocyclyl-O—, C3-10-carbocyclyl-C1-3-alkyl-O—, C1-6-alkyl-S—, C3-10-carbocyclyl-S—, C3-10-carbocyclyl-C1-3-alkyl-S—, C1-4-alkyl-C(═O)—, C1-4-alkyl-S(═O)2—, R3R4—N—, R3R4—N—C1-3-alkyl-, R3R4—N—CO—, C1-4-alkyl-C(═O)—R4N—C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl-, aryl, aryl-C1-3-alkyl-, heteroaryl-C1-3-alkyl- and heteroaryl,
• wherein in each carbocyclyl and heterocyclyl a CH2-group may be replaced by —C(═O)—,
• wherein each carbocyclyl and heterocyclyl may be substituted with one or more C1-4-alkyl, which may be substituted with one or more substituents R2,
• wherein each alkyl, carbocyclyl and heterocyclyl may be substituted with one or more substituents R2, and
• wherein each aryl and heteroaryl group may be substituted with one or more substituents R5,
• including any tautomers and stereoisomers thereof,
• or a pharmaceutically acceptable salt thereof.